OTCPK:HGEN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Humanigen, Inc., a biopharmaceutical company, develops proprietary monoclonal antibodies for immunotherapy and oncology treatments.


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has Humanigen's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HGEN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

58.0%

HGEN

0.5%

US Biotechs

3.0%

US Market


1 Year Return

18.8%

HGEN

27.3%

US Biotechs

9.9%

US Market

Return vs Industry: HGEN underperformed the US Biotechs industry which returned 27.6% over the past year.

Return vs Market: HGEN exceeded the US Market which returned 9.5% over the past year.


Shareholder returns

HGENIndustryMarket
7 Day58.0%0.5%3.0%
30 Day68.6%9.2%8.2%
90 Day351.4%12.8%0.4%
1 Year18.8%18.8%28.6%27.3%12.4%9.9%
3 Year-31.3%-31.3%34.7%30.2%31.0%22.3%
5 Year-67.3%-67.3%-1.9%-7.8%58.1%40.3%

Price Volatility Vs. Market

How volatile is Humanigen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Humanigen undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Humanigen is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Humanigen has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of HGEN’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Humanigen regulatory filings here.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is Humanigen forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

30.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Humanigen has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Humanigen performed over the past 5 years?

27.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HGEN is currently unprofitable.

Growing Profit Margin: HGEN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: HGEN is unprofitable, but has reduced losses over the past 5 years at a rate of 27.6% per year.

Accelerating Growth: Unable to compare HGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: HGEN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Humanigen's financial position?


Financial Position Analysis

Short Term Liabilities: HGEN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: HGEN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: HGEN has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: HGEN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HGEN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if HGEN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Humanigen's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HGEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HGEN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HGEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average board tenure


CEO

Cameron Durrant (59yo)

4.17yrs

Tenure

US$784,500

Compensation

Dr. Cameron Durrant, MD, MBA, is the Chairman and Chief Executive Officer of Humanigen, since January 2016 and serves as its Interim Chief Financial Officer since July 1, 2019. He also serves as the Direct ...


CEO Compensation Analysis

Compensation vs Market: Cameron's total compensation ($USD784.50K) is below average for companies of similar size in the US market ($USD1.38M).

Compensation vs Earnings: Cameron's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Cameron Durrant
Chairman4.17yrsUS$784.50k0.44% $827.4k
Robert Savage
Independent Director2.17yrsUS$74.00k0.16% $296.8k
Rainer Boehm
Independent Director2.17yrsUS$66.00k0.33% $619.8k
Cheryl Buxton
Independent Director0.42yrUS$232.25k0.012% $22.9k
Ronald Barliant
Independent Director4.33yrsUS$54.00k0.36% $667.3k
Timothy Morris
Independent Director3.83yrsUS$66.00kno data

3.0yrs

Average Tenure

59yo

Average Age

Experienced Board: HGEN's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.5%.


Top Shareholders

Company Information

Humanigen, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Humanigen, Inc.
  • Ticker: HGEN
  • Exchange: OTCPK
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$187.617m
  • Shares outstanding: 126.34m
  • Website: https://www.humanigen.com

Number of Employees


Location

  • Humanigen, Inc.
  • 533 Airport Boulevard
  • Suite 400
  • Burlingame
  • California
  • 94005
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HGENOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJan 2013

Biography

Humanigen, Inc., a biopharmaceutical company, develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company’s lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes granulocyte-macrophage colony-stimulating factor, which is in Phase I/II clinical trial in patients with chronic myelomonocytic leukemia, and for the treatment of juvenile myelomonocytic leukemia. It also develops Ifabotuzumab, a monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005 an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic diseases. The company has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase I/II study of lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/31 05:34
End of Day Share Price2020/05/29 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.